Brodalumab in an Organ Transplant Recipient With Psoriasis

Singh, Inderpreet; Uy, Angeline; Kassardjian, A.; Armstrong, April W.

doi:10.12788/cutis.0167

Cited by 8 publications

(11 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are three case reports of the use of IL‐17 inhibitors in SOT recipients 38–40 . Di Altobrando et al.…”

Section: Agentsmentioning

confidence: 99%

“…Singh et al. described a LT recipient who developed a psoriasis flare‐up 1 year post‐transplant treated with brodalumab, but immunosuppression detail was not included in the report 40 …”

Section: Agentsmentioning

confidence: 99%

“…A systematic review reported the overall incidences of Candida infections as 1.7–4%; the infections were mild to moderate in severity, did not interrupt treatment, and resolved with appropriate therapy 54 . In case reports of ixekizumab and brodalumab in SOT recipients, no infections were observed during the 6 months to 1 year follow‐up 38–40 . The risk of serious infection associated with IL‐17 inhibitors appears low.…”

Section: Agentsmentioning

confidence: 99%

“…39 Singh et al described a LT recipient who developed a psoriasis flare-up 1 year post-transplant treated with brodalumab, but immunosuppression detail was not included in the report. 40 There is no published data on the use of IL-23 inhibitors guselkumab, risankizumab, or tildrakizumab in solid organ transplant recipients.…”

Section: Changes To Induction and Maintenance Immunosuppressionmentioning

confidence: 99%

“…54 In case reports of ixekizumab and brodalumab in SOT recipients, no infections were observed during the 6 months to 1 year follow-up. [38][39][40] The risk of serious infection associated with IL-17 inhibitors appears low. Other IL-inhibitors such as dupilumab have not demonstrated increased risks of infection in case reports of SOT patients.…”

Section: Based On Clinical Circumstance and Theoretical Concerns Cons...mentioning

confidence: 99%

See 4 more Smart Citations

The use of non‐transplant biologics in solid organ transplant recipients: A practical review for the frontline clinician

Szczepanik

Choi

Brady

et al. 2022

Clinical Transplantation

View full text Add to dashboard Cite

Biologics have become the forefront of medicine for management of autoimmune conditions, leading to improved quality of life. Many autoimmune conditions occur in solid organ transplant (SOT) recipients and persist following transplant. However, the use of biologics in this patient population is not well studied, and questions arise related to risk of infection and adjustments to induction and maintenance immunosuppression. Guidelines have been published highlighting management strategies of biologics around the time of elective surgical procedures, but this is not always feasible in urgent situations, especially with deceased donor transplantation. The aim of this review is to summarize the current literature regarding the use of these agents in solid organ transplant recipients, and specifically address induction and maintenance immunosuppression, as well as the need for alternative infective prevention strategies to create This paper represents the opinion of the Immunology/Transplantation Practice and Research Network of the American College of Clinical Pharmacy. It does not necessarily represent an official ACCP commentary, guideline, or statement of policy or position.

show abstract

“…There are three case reports of the use of IL‐17 inhibitors in SOT recipients 38–40 . Di Altobrando et al.…”

Section: Agentsmentioning

confidence: 99%

Section: Agentsmentioning

confidence: 99%